Pulse Biosciences (NASDAQ:PLSE) and Neovasc (NASDAQ:NVCN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.
Earnings & Valuation
This table compares Pulse Biosciences and Neovasc’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pulse Biosciences||N/A||N/A||-$37.54 million||($2.20)||-4.97|
|Neovasc||$1.75 million||12.61||-$108.04 million||($27.30)||-0.11|
Pulse Biosciences has higher earnings, but lower revenue than Neovasc. Pulse Biosciences is trading at a lower price-to-earnings ratio than Neovasc, indicating that it is currently the more affordable of the two stocks.
This table compares Pulse Biosciences and Neovasc’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Pulse Biosciences has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500. Comparatively, Neovasc has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.
This is a summary of recent ratings for Pulse Biosciences and Neovasc, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Pulse Biosciences presently has a consensus price target of $27.00, indicating a potential upside of 146.80%. Given Pulse Biosciences’ higher probable upside, research analysts clearly believe Pulse Biosciences is more favorable than Neovasc.
Insider & Institutional Ownership
9.2% of Pulse Biosciences shares are held by institutional investors. Comparatively, 10.0% of Neovasc shares are held by institutional investors. 48.6% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Pulse Biosciences beats Neovasc on 8 of the 12 factors compared between the two stocks.
About Pulse Biosciences
Pulse Biosciences, Inc. operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.